• Yung-Tsu Cho, Tom C Chan, Chih-Hung Lee, Wan-Yi Chou, Pa-Fan Hsiao, Yi-Ju Chen, Po-Yuan Wu, Che-Wen Yang, Tsu-Man Chiu, Yun-Ting Chang, Wei-Ming Wang, Chien-Hui Hong, Wei-Ting Tu, Yu-Huei Huang, Tsen-Fang Tsai, Cheng-Che Lan, and Chia-Yu Chu.
• Chen YY's Clinic, Keelung, Taiwan; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
• J Formos Med Assoc. 2022 Jul 1; 121 (7): 119112031191-1203.

AbstractUrticaria is a prevalent disease with substantial physical, psychological, and economic impacts. With the advent of understandings of the disease and the emerging evidence of treatments, the international guidelines for treating urticaria have been updated in recent years. In order to update the 2014 edition of the Taiwanese Dermatological Association (TDA) consensus of urticaria, a total of 17 dermatologists with extensive experience in urticaria management were invited to and attended the TDA consensus meetings. All the specific aspects of the content were approved by at least 75% of the experts in attendance. Comparing to the former edition, several substantial modifications were made. For diagnosis, D-dimer was added as the recommended routine test in patients with chronic spontaneous urticaria. For pharmacological management, treatment suggestions were simplified. The approved-dosed, the up-dosed second-generation antihistamines, omalizumab, and cyclosporine were listed as the first-line to the fourth-line treatment, respectively. In addition, the management for patients of special considerations, such as the elderly, children, and pregnant women, were all discussed and mentioned in the consensus. We hope the updated TDA consensus can serve as a reference for all physicians and can help the physicians providing up-to-dated managements for these patients.Copyright © 2022 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

18 keywords...

hide…